학술논문

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Document Type
Journal
Source
BLOOD; NOV 13 2019, 134 4p. Supplement: 1
Subject
Language
English
ISSN
15280020